Treatment of TNNT1-Myopathy With L-Tyrosine.

Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02035501

Enrollment

Registered

2014-01-14

Start date

2014-01-31

Completion date

Unknown

Last updated

2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nemaline Myopathy

Brief summary

The purpose of the study is to investigate if treatment with L-Tyrosine improves selected outcome measures of TNNT1 myopathy.

Interventions

DRUGL-Tyrosine

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

No minimum to 20 Years

Inclusion criteria

* Male or female patients * any age with TNNT1-related myopathy

Exclusion criteria

* Patients who are non-cooperative or parents/ legal guardians who are unwilling to sign consent form

Design outcomes

Primary

Measure	Time frame
1. goal attainment score	3 month

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026